Nektar Therapeutics provided earnings guidance for the year 2023. GAAP revenue for the full year 2023 is expected to be between $80 million and $90 million. This revenue includes $65 million to $70 million in noncash royalties and $15 million to $20 million in product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | -2.44% | -4.19% | +183.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+183.19% | 301M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2023